Final report on the safety assessment of piper methysticum Leaf/Root/Stem extract and piper methysticum root extract

International Journal of Toxicology

Volumn 28, Issue 6_suppl, 2009, Pages 175S-188S

  Robinson, Valerie ^a   Bergfeld, Wilma F ^a   Belsito, Donald V ^a   Klaassen, Curtis D ^a   Marks, James G ^a   Shank, Ronald C ^a   Slaga, Thomas J ^a   Snyder, Paul W ^a   Andersen, F Alan ^a  

^a Cosmetic Ingredient Review ^*  (United States)

Author keywords

Cosmetics; Piper methysticum leaf root stem extract and Piper methysticum root extract; Safety

Indexed keywords

10 METHOXYYANGONIN; 11 HYDROXYYANGONIN; 11 METHOXYYANGONIN; 5 HYDROXY 7,8 DIHYDROKAVAIN; 5 HYDROXYKAVAIN; 5,6 DEHYDROMETHYSTICIN; 5,6 DIHYDROYANGONIN; 5,6,7,8 TETRAHYDROYANGONIN; 7,8 DIHYDROYANGONIN; COSMETIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEMETHOXYYANGONIN; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; KAVA EXTRACT; KAWAIN; METHYSTICIN; PIPER METHYSTICUM LEAF ROOT STEM EXTRACT; PIPER METHYSTICUM ROOT EXTRACT; PLANT MEDICINAL PRODUCT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; YANGONIN; KAVA; PLANT EXTRACT; PYRAN DERIVATIVE; PYRONE DERIVATIVE;

ARTICLE; CARCINOGENICITY; CHEMICAL COMPOSITION; CHRONIC TOXICITY; CLINICAL ASSESSMENT; CYTOTOXICITY; DEVELOPMENTAL TOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HUMAN; LIVER INJURY; NEUROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; RISK ASSESSMENT; SKIN ABSORPTION; ANIMAL; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PLANT LEAF; PLANT ROOT; PLANT STEM; SKIN CARE; TOXIC HEPATITIS; TOXICITY TESTING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; COSMETICS; DRUG-INDUCED LIVER INJURY; HUMANS; KAVA; PLANT EXTRACTS; PLANT LEAVES; PLANT ROOTS; PLANT STEMS; PYRANS; PYRONES; SKIN CARE; TOXICITY TESTS;

EID: 77949899280     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809350934     Document Type: Article

References (70)

1. FDA. Consumer advisory: Kava-containing dietary supplements may be associated with severe liver injury. 2002. http:// wwwcfsanfdagovdms/aadskvahtml. Accessed June 17, 2003.
2. FDA. Letter to health care professionals: FDA issues consumer advisory that Kava products may be associated with severe liver injuries. 2002. http://wwwcfsanfdagovdms/ds-ltr29html. Accessed June 17, 2003.
3. Gottschalck TE, McEwen GN Jr. International Cosmetic Ingredient Dictionary and Handbook. 10th ed. Washington, DC: CTFA; 2006.
4. Singh YN. Kaa: an overview. J Ethnopharmacol. 1992;37:13-45.
5. Duve RN. Gas Liquid chromatographic determination of major constituents of Piper Methysticum. Analyst. 1981;106:160-165.
6. Cheng D, Lidgard RO, Duffield PH, Duffield AM, Brophy JJ. Identification by methane chemical ionization gas chromatography/ mass spectrometry of the products obtained by steam distillation an aqueous acid extraction of commericial Piper Methsticum. Biomed Environ Mass Spectrom. 1988;17:371-376.
7. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetic. 2nd edition. New York, NY: John Wiley; 1996.
8. Kinder C, Cupp MJ. Kava-an herbal sedative. Nurse Pract. 1998;23:14.
9. Dragull K, Yoshida WY, Tang CS. Piperidine alkaloids from Piper Methysticum. Phytochemistry. 2003;63:193-198.
10. Lim STS, Dragull K, Tang C-S, Bittenbender HC, Efird JT, Nerurkar PV. Effects of kava alkaloid, pipermethysine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci. 2007;97:214-221.
11. Ramzan I, Tran VH. Chemistry of kava and kavalactones. In: Kava: From Ethnology to Pharmacology. Boca Raton, FL: CRC Press; 2004:78-103.
12. Budavari, S. ed. 1989. the Merck index. An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th ed. Rahway, NJ: Merck and Co., Inc.
13. Schultz J, Siegers CP. Toxicity of kavapyrones, drug safety, and precautions-a case study. Phytomedicine. 1998;10:68-73.
14. Kubatova A, Hawthorne S. Comparison of subcritical water and organic solvents for extracting kavalactones from kava root. J Chromatog A. 2001;923:187-194.
15. Eschar M, Desmeules J, Giostra E, Mentha G. Drug points: hepatitis associated with Kava, a herbal remedy for anxiety. BMJ. 2001;322:1097.
16. Duve RN, Prasad J. Changes in the chemical composition of ""yagona'' (Piper Methysticum) with time. Fiji Agricultural Journal. 1983;45:45-50.
17. Cosmetic, Toiletry, and Fragrance Association (CTFA). Concentration of use information for Piper Methysticum-derived ingredients. 2006.
18. Cawte J. Parameters of kava used as a challenge to alcohol. Aust NZ J Psychiatry. 1985;20:70-76.
19. Singh YN. Kava: an overview. J Ethnopharmacol. 1992;37:13-45.
20. Meyer HJ. Pharmacology of kava. Psychopharmacol Bull. 1967;4:10-11.
21. Rasmussen AK, Scheline E, Solheim E, Hansel R. Metabolism of some kava pyrones in the rat. Xenobiotica. 1979;9:1-16.
22. Locher CP, Burch MT, Mower HF. Anti-microbial activity and anti-complement activity of extracellular obtained selected Hawaiian medicinal plants. J Ethnopharmacol. 1995;49:23-32.
23. Matthews JM, Etheridge AS, Black SR. Short communication: inhibition of human cytochrom P450 activities by Kava extract and kavalactones. Drug Metab. 2002;30:1153-1157.
24. Avdeef A, Strafford M, Block E. Drug absorption in vitro model: filter-immobilized artificial membranes, 2: studies of the permeability properties of lactones in Piper Methysticum Forst. Eur J Pharm Sci. 2001;14:271-280.
25. Chromadex. Kava-kava-Piper Methysticum G. Forster (Piperacae). 2004. http://www.chromadexcom/phytosearch/kavakava/ htm. Accessed August 11, 2004.
26. DiSilvestro RA, Zhang W, DiSilvestro DJ. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. Food Chem Toxicol. 2007;45:1293-1300.
27. Hapke HJ, Sterner W, Heisler E, Brauer H. Toxicological studies with Kavaform. Farmaco Prat. 1971;26:692-720.
28. Hashimoto T, Suganuma M, Fujiki H, Yamada M, Kohno T, Asakawa Y. Isolation and synthesis of TNF-alpha release inhibitors from Fijian kawa (Piper Methysticum). Phytomedicine. 2003;10:309-317.
29. He X-G, Lomgze L, Lian L-Z. Electrospray high performance liquid chromatography-mass spectrometry in phytochemical analysis of kava (Piper Methysticum) extract. Plant Med. 1997; 63:70-74.
30. Health Canada. Advisory: Health Canada issues a stop-sale order for all products containing kava. 2002. http://wwwhcscgcca/english/ protection/warnings/2002/2002-56ehtm. Accessed April 5, 2004.
31. Heinze HJ, Munthe TF, Steitz J, Matzke M. Pharmopsychological effects of oxazepam and kava-extract in a visual search paradigm assesed with event-related potentials. Pharmacopsychiatry. 1994;27:224-230.
32. Duffield PH, Jamieson DD, Duffield AM. Effect of aqueous and lipid-soluble extracts of kava on the conditioned avoidance response in rats. Arch Int Pharmacodyn ther. 1989;301:81-90.
33. Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol. 1991;18:571-578.
34. Jamieson DD, Duffield PH, Cheng D, Duffield AM. Comparison of the dentral nervous system activity of the aqueous and lipid extract of kava (Piper Methysticum). Arch Int Pharmacodyn ther. 1989;301:66-80.
35. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics. 2nd ed. New York, NY: John Wiley; 1996.
36. Wu D, Yu L, DeWitt DL. Novel compounds from Piper methysticum Forst (Kava Kava) roots and their effect on cyclogenase enzyme. J Agric Food Chem. 2002;50:701-705.
37. Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (kava-kava). Planta Med. 2002;68:1055-1058.
38. Matthews JM, Etheridge AS, Black SR. Short communication: inhibition of human cytochrom P450 activities by Kava extract and kavalactones. Drug Metabolism. 2002;30:1153-1157.
39. Zou L, Dike LE. Kava does not display metabolic toxicity in a homogenous cellular assay. Planta Med. 2004;70:289-292.
40. Coté CS, Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial Kava extracts. Biochem Biophys Res Comm. 2004;322:147-152.
41. Gleitz J, Beile Z, Wilkens P, Ameri A, Peters T. Antithrombotic action of the kava pyrone (Th0- kavain prepared from Piper Methysticum on human platelets. Planta Med. 1997;63:27-30.
42. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kave pryone-enriched extract from Piper Methysticum Forster (kava-kava). Pharmacopsychiatry. 1998;31:187-192.
43. Nerurkar PV, Dragull K, Tang C-S. In vitro toxicity of kava alkaloid, pipermethstine, in HepG2cells compared to kavalactones. Toxico Sci. 2004;79:106-111.
44. Steiner GG. the Correlation between cancer incidence and kava consumption. Hawaii Med J. 2001;59:420-422.
45. Van Dam-Bakker AW, De Groot AP, Luyken R. Influence of Wati (Piper Methysticum) on the fertility of male rats. Trop Geogr Med. 1958;10:68-70.
46. Meyer HJ. Pharmacology of kava. Psychopharmacol Bull. 1967;4:10-11.
47. Singh YN, Devkota AK. Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 2003;69:496-499.
48. Lim STS, Dragull K, Tang C-S, Bittenbender HC, Efird JT, Nerurkar PV. Effects of kava alkaloid, pipermethysine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci. 2007;97:214-221.
49. Hapke HJ, Sterner W, Heisler E, Brauer H. Toxicological studies with Kavaform. Farmaco Prat. 1971;26:692-720.
50. DiSilvestro RA, Zhang W, DiSilvestro DJ. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. Food Chem Toxicol. 2007;45:1293-1300.
51. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol. 1990;17: 509-514.
52. Hsu SY, Lin MH, Lin LC, Chou CJ. Toxicologic studies of dihydro-5, 6-dehydrokawain and 5,6-dehydrokawain. Planta Med. 1994;60:88-90.
53. National Toxicology Program (NTP). NTP testing status-Kava Kava Extract. 2006. http://ntpniehsnihgov/index/cfm?objectid=0715156E-C6E1-7AAA-C90C751E23D14C1B. Accessed July 11, 2006.
54. Schelosky LC, Raffauf K, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry. 1995; 58:639-640.
55. Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of Kava intoxication. Med J Aust. 1997;167:172-173.
56. Russman S, Helbling A. Kava hepatoxicity. Ann Intern Med. 2001;135:68-69.
57. Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with Kava-containing products-United States, Germany, and Switzerland, 1999-2002. MMRW Morb Mortal Wkly Rep. 2003;51:1065-1067.
58. Humberston CL, Krenzelok EP. Acute hepatitis induced by kavakava. J Toxicol Clin Toxicol. 2003;41:109-113.
59. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125:940-941.
60. Garner LF, Klinger JD. Some visual effects caused by the beverage kava. J Enthnopharmacol. 1985;13:307-311.
61. Kraft M, Spahn TW, Menzel J, et al. Fulminant liver failure after administration of the herbal antidepressant kava-kava. Dtsch Med Wochenschr. 2001;126:970-972.
62. Keledijian J, Duffield PH, Jamieson DD, Lidgard RO, Duffield AM. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J Pharm Sci. 1988; 77:1003-1006.
63. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol. 1994;31:89-97.
64. Ruze P. Kava-induced dermopathy: A nicacin deficiency? Lancet. 1990;335:1442-1445.
65. Lebot V. Kava, the Pacific Drug. New Haven, CT: Yale University Press; 1992.
66. Jappe U, Franke I, Reinhold D, Gollnick HP. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol. 1998;31:104-104.
67. Food and Drug Administration (FDA). Letter to healthcare professionals concerning Kava. 2001. http://fdagov/medwatch/ SAFETY/2001/kavahtm. Accessed June 17, 2003.
68. Bilia AR, Bergonzi MC, Lazari D, Vincieri FF. Characterization of commercial kava-kava herbal drug and herbal drug preparationd by means of nuclear magnetic resonance spectroscopy. J Agric Food Chem. 2002;50:5016-5025.
69. Rasmussen AK, Scheline E, Solheim E, Hansel R. Metabolism of some kava pyrones in the rat. Xenobiotica. 1979; 9:1-16.
70. FDA. Frequency of Use of Cosmetic Ingredients. Washington, DC: US Food and Drug Administration; 2006.